Selecting and Sequencing First-Line Therapy in ALK-Positive NSCLC

This segment focuses on treatment selection and disease monitoring for patients with ALK-positive NSCLC. Faculty discuss factors that influence frontline treatment decisions, including central nervous system involvement, disease burden, and patient-specific considerations. The panel reviews approaches to counseling patients prior to treatment initiation and examines how efficacy and tolerability factor into therapeutic decision-making. Discussion also addresses strategies for monitoring treatment response, evaluating disease progression, and incorporating tissue and liquid biopsy at progression. In addition, faculty review resistance mechanisms that may emerge during treatment and discuss how molecular findings can help guide subsequent management decisions. The conversation highlights considerations involved in the ongoing care of patients receiving ALK-directed therapies.